Arcellx (NASDAQ:ACLX) Downgraded by Robert W. Baird to Hold

Arcellx (NASDAQ:ACLX) was downgraded by analysts at Robert W. Baird from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

ACLX has been the subject of a number of other research reports. Wolfe Research began coverage on Arcellx in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Canaccord Genuity Group set a $115.00 price objective on Arcellx in a report on Monday. HC Wainwright downgraded Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 target price for the company. in a report on Monday. William Blair lowered Arcellx from a “strong-buy” rating to a “market perform” rating in a research report on Monday. Finally, Truist Financial set a $120.00 price target on shares of Arcellx in a report on Monday. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $111.29.

Arcellx Trading Up 77.4%

NASDAQ ACLX opened at $113.75 on Monday. Arcellx has a 12-month low of $47.86 and a 12-month high of $114.26. The company has a fifty day simple moving average of $67.89 and a two-hundred day simple moving average of $75.07. The stock has a market cap of $6.58 billion, a P/E ratio of -28.94 and a beta of 0.36.

Insiders Place Their Bets

In other Arcellx news, insider Christopher Heery sold 7,437 shares of Arcellx stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total value of $487,197.87. Following the completion of the transaction, the insider owned 29,631 shares of the company’s stock, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 19,450 shares of company stock valued at $1,283,477 over the last three months. 8.35% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arcellx

Several institutional investors and hedge funds have recently modified their holdings of ACLX. MAI Capital Management acquired a new position in Arcellx in the 3rd quarter worth about $26,000. CWM LLC increased its position in shares of Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock valued at $28,000 after buying an additional 251 shares in the last quarter. State of Wyoming acquired a new position in shares of Arcellx during the 2nd quarter worth approximately $28,000. Ramirez Asset Management Inc. purchased a new position in shares of Arcellx during the 3rd quarter valued at approximately $41,000. Finally, Abich Financial Wealth Management LLC acquired a new stake in Arcellx in the 3rd quarter valued at $62,000. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Arcellx News Roundup

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Acquisition announcement — Gilead agreed to acquire Arcellx for $115 cash per share plus a $5 CVR (implied equity value ~$7.8B). This takeover premium explains the sharp upward move and converts future biotech risk into a near‑term cash outcome for shareholders. Gilead Sciences to Acquire Arcellx (Business Wire)
• Positive Sentiment: Strategic rationale — Coverage explains what Gilead gets (Anito‑cel and related assets) and why the deal fits Gilead’s oncology push, supporting the acquisition premium investors priced in. What Gilead Is Getting (Seeking Alpha)
• Neutral Sentiment: Analyst/coverage context — Wells Fargo reaffirmed an “equal weight” rating and a $115 price target (effectively aligned with the cash offer), signaling limited upside beyond the deal price for remaining arbitrage. Wells Fargo rating/target (The Fly)
• Neutral Sentiment: Market commentary — Broad coverage (Reuters/Investopedia/WSJ) recounts the deal and the market reaction; useful for context but unlikely to change deal economics. Gilead to acquire Arcellx (Reuters)
• Negative Sentiment: Shareholder investigations — Multiple law firms have launched probes into whether Arcellx’s sale process and price were fair to public shareholders (Monteverde, Ademi, Halper Sadeh, etc.), which could lead to litigation, delays or demands for higher consideration. Monteverde shareholder alert (PR Newswire)
• Negative Sentiment: Analyst downgrade — Needham cut ACLX from Buy to Hold, which can temper post‑deal sentiment among some buy‑side investors. Needham downgrade (The Fly)
• Negative Sentiment: Prior institutional selling — Perceptive Advisors disclosed a large fourth‑quarter sale of ACLX shares before the deal, a reminder some holders trimmed exposure; combined with litigation risk this could sustain selling pressure from certain shareholders. Perceptive Advisors share sale (Motley Fool)

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.